Navigation Links
OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Program Overview and Reports Financial Results for First Quarter 2013
Date:5/2/2013

BOTHELL, Wash. and VANCOUVER, British Columbia, May 2, 2013 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today provided an overview of clinical development activities for its two product candidates, custirsen and OGX-427, and announced first quarter 2013 financial results.

OGX-427 Program Update

  • In January 2013, the Company initiated the ORCA™ (Ongoing Studies Evaluating Treatment Resistance in CAncer) program, encompassing clinical trials of its unpartnered product candidate, OGX-427, across multiple cancer indications.  Trials evaluating the addition of OGX-427 to commonly used anticancer therapies in patients with advanced bladder, lung, pancreatic and prostate cancers have been announced, with additional updates to the ORCA program expected to be provided later this year.
  • The Borealis-1™ Trial is a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer. This global trial aims to enroll approximately 180 patients and is expected to complete patient accrual in the second half of 2013.
  • The Borealis-2™ Trial is an investigator-sponsored, randomized Phase 2 trial evaluating OGX-427 in combination with docetaxel in patients with advanced or metastatic bladder cancer who have disease progression following first-line platinum-based chemotherapy.  Borealis-2 was initiated in April of 2013 and aims to enroll approximately 200 patients.
  • The Spruce™ Trial is an investigator-sponsored, randomized, placebo-controlled Phase 2 trial evaluating OGX-427 in combination with carboplatin and pemetrexed in patients with previously untreated, advanced, non-squamous, non-small cell lung cancer (NSCLC). Plans for Spruce were announced in Apri
    '/>"/>

  • SOURCE OncoGenex Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. OncoGenex Pharmaceuticals, Inc. Provides Update on Clinical Development Program and Reports Financial Results for Fourth Quarter and Year End 2012
    2. OncoGenex Announces Plans for the Initiation of the Borealis-2 Clinical Trial Evaluating OGX-427 in Combination with Second-Line Therapy for Bladder Cancer
    3. OncoGenex Announces Initiation of the Phase 3 "AFFINITY" Trial for Patients with Advanced Prostate Cancer
    4. OncoGenex Pharmaceuticals, Inc. Reports Second Quarter and First-Half 2012 Financial Results and Reviews Clinical Development Highlights for Custirsen and OGX-427
    5. Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company launch educational campaign about emerging science in type 2 diabetes
    6. Cactus Ventures, Inc. Changes Name to Actinium Pharmaceuticals, Inc.
    7. Omthera Pharmaceuticals, Inc. Announces Closing of Initial Public Offering
    8. Avion Pharmaceuticals, LLC., announces further expansion of their Womens Health Sales Team
    9. Omthera Pharmaceuticals, Inc. Announces Pricing of Initial Public Offering
    10. Covis Pharmaceuticals, Inc Named US Distributor For Five Additional Products
    11. Edison Pharmaceuticals, Inc. signs licensing agreement with Dainippon Sumitomo Pharma Co., Ltd. for development & commercialization of orphan mitochondrial and adult central nervous system disease drugs
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/21/2015)... 21, 2015  When Ryan Rendino first ... of his neck, he figured it was ... weeks off from weight lifting. ... A series of doctor ... to Michel Kliot, MD , a ...
    (Date:5/21/2015)... 2015  CryoLife, Inc. (NYSE: CRY ), a ... cardiac and vascular surgery, announced today that its Board ... the second quarter 2015 of $0.03 per share of ... per share will be paid on June 19, 2015 ... 12, 2015.  The ex-dividend date for the quarterly dividend ...
    (Date:5/21/2015)... Mai 2015 Dipexium Pharmaceuticals, ... Unternehmen für Arzneimittel im fortgeschrittenen Entwicklungsstadium, ... Vermarktung von Locilex® (Pexiganan-Creme 0,8 %) und ... wissenschaftliche Posterpräsentation an, welche das innovative ... OneStep-1 und OneStep-2, in der Locilex® ...
    Breaking Medicine Technology:Northwestern Medicine Surgeons Develop New Approach to Removing Nerve Tumors 2Northwestern Medicine Surgeons Develop New Approach to Removing Nerve Tumors 3Northwestern Medicine Surgeons Develop New Approach to Removing Nerve Tumors 4CryoLife Announces Quarterly Cash Dividend for the Second Quarter 2015 2Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an 2Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an 3Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an 4Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an 5Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an 6Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an 7
    ... BIRMINGHAM, Ala., Oct. 23 BioCryst Pharmaceuticals, Inc. (Nasdaq: ... and Drug Administration (FDA), in response to a request ... (CDC), has issued an emergency use authorization (EUA) for ... adult and pediatric patients with confirmed or suspected 2009 ...
    ... Sanovia, a leading provider of pharmacy utilization ... selected by HealthSpring, Inc. to deliver its PA-Logic(TM) ... the largest Medicare Advantage coordinated care plans in ... in delivering pharmaceutical prior authorization solutions that help ...
    Cached Medicine Technology:Emergency Use Authorization Granted For BioCryst's Peramivir 2Emergency Use Authorization Granted For BioCryst's Peramivir 3Emergency Use Authorization Granted For BioCryst's Peramivir 4Sanovia Selected to Deliver PA-Logic(TM) Pharmaceutical Prior Authorization Platform to HealthSpring 2Sanovia Selected to Deliver PA-Logic(TM) Pharmaceutical Prior Authorization Platform to HealthSpring 3
    (Date:5/24/2015)... Indiana Fiber Network, LLC (IFN), the leading Indiana ... Inc. (MTA) has selected IFN as a fiber transport ... Sales Manager, fiber route diversity and network redundancy are ... MTA with the diverse fiber transport from their Merrillville ... voice carriers located at Henry Street in Indianapolis, IN. ...
    (Date:5/23/2015)... On Saturday, May 23, 2015, over 100 ... Branches Florida City exactly five years to the day after ... , A large fire tore through the Branches United Methodist ... in the middle of the night as neighbors, staff and ... arson even though it is suspected that the fire began ...
    (Date:5/23/2015)... New York, NY (PRWEB) May 23, 2015 ... (CareFirst) announced that, “the company has been the ... discovered as a part of the company’s ongoing Information ... cyberattacks on health insurers.” , The most notable ... this year when Anthem Inc., the nation’s second largest ...
    (Date:5/23/2015)... Javon Bea Mercy Health System ... and Rehabilitation Center, 557 N. Washington St., Janesville, will ... 20, 5:30-6:30 pm. , The 8-week clinic is lead ... RN, BSN, who will offer training that encompasses a ... mechanics and show selection and weekly training plans. , ...
    (Date:5/22/2015)... OR (PRWEB) May 22, 2015 Pioneer ... remains at the forefront of designing with reclaimed wood, ... Design in Los Angeles, California. Their newest offerings, Vat ... bring much-anticipated surface and color to America's largest design ... our exhibit at each show, anxious to see and ...
    Breaking Medicine News(10 mins):Health News:Indiana Fiber Network, LLC Enables Midwest Telecom of America with Fiber Route Diversity 2Health News:Five Years After Fire, Branches Rebuilds Playground 2Health News:One Headline Making Cyber Attack Sparks Discovery of Another 2Health News:One Headline Making Cyber Attack Sparks Discovery of Another 3Health News:One Headline Making Cyber Attack Sparks Discovery of Another 4Health News:Pioneer Millworks to Reveal New Design Trends with Reclaimed Wood at Dwell on Design in LA 2Health News:Pioneer Millworks to Reveal New Design Trends with Reclaimed Wood at Dwell on Design in LA 3
    ... a 38-year-old man with Lou Gehrig,s disease, releases a piano ... ALS Awareness Month.Words like "inspiring" get used so casually that ... Noface, and his new album, Toxic Charm, one immediately becomes ... courage. The musician, living with a terminal illness, is facing ...
    ... (Nasdaq: MYL ) today announced that its ... U.S. Food and Drug Administration (FDA) for its Abbreviated ... mg, and Mycophenolate Mofetil Capsules, 250 mg. Mycophenolate Mofetil ... indicated for the prevention of organ rejection in patients ...
    ... Wales, May 7 Glan Clywd Hospital will soon ... radiotherapy treatments using RapidArc(TM) radiotherapy technology on two new ... VAR ). When the Clinac(R) linear accelerators with ... the first in Wales to offer this new, faster ...
    ... , , Fiscal third quarter revenue ... quarter a year ago , , , , ... were a record $0.50 per share , , , , ... revenue increased by $46 million or 12% , , , ...
    ... 11 years combines unique Stereo Precision Technology(TM) optics and ... stay in contacts longerJACKSONVILLE, Fla., May 7 VISTAKON(R), ... announced plans to introduce ACUVUE(R) OASYS(TM) Brand ... which is the first new multifocal contact lens from ...
    ... 7, 08:30 a.m. EDT at www.isispharm.com CARLSBAD, Calif., ... ) today announced its financial results for the quarter ended ... $171.8 million gain that Isis recognized from selling its Ibis ... first quarter of 2009 with pro forma net income of ...
    Cached Medicine News:Health News:ALS Musician Composes CD with One Finger 2Health News:Cancer Patients in North Wales to Gain Access to Varian's RapidArc Radiotherapy Treatments 2Health News:Perrigo Reports Record Third Quarter 2Health News:Perrigo Reports Record Third Quarter 3Health News:Perrigo Reports Record Third Quarter 4Health News:Perrigo Reports Record Third Quarter 5Health News:Perrigo Reports Record Third Quarter 6Health News:Perrigo Reports Record Third Quarter 7Health News:Perrigo Reports Record Third Quarter 8Health News:Perrigo Reports Record Third Quarter 9Health News:Perrigo Reports Record Third Quarter 10Health News:Perrigo Reports Record Third Quarter 11Health News:Perrigo Reports Record Third Quarter 12Health News:Perrigo Reports Record Third Quarter 13Health News:Perrigo Reports Record Third Quarter 14Health News:Perrigo Reports Record Third Quarter 15Health News:Perrigo Reports Record Third Quarter 16Health News:Perrigo Reports Record Third Quarter 17Health News:Perrigo Reports Record Third Quarter 18Health News:Perrigo Reports Record Third Quarter 19Health News:Perrigo Reports Record Third Quarter 20Health News:Perrigo Reports Record Third Quarter 21Health News:Perrigo Reports Record Third Quarter 22Health News:VISTAKON to Introduce ACUVUE(R) OASYS(TM) Brand Contact Lenses for PRESBYOPIA 2Health News:VISTAKON to Introduce ACUVUE(R) OASYS(TM) Brand Contact Lenses for PRESBYOPIA 3Health News:VISTAKON to Introduce ACUVUE(R) OASYS(TM) Brand Contact Lenses for PRESBYOPIA 4Health News:Isis Reports Strong Financial Results and Highlights for First Quarter of 2009 2Health News:Isis Reports Strong Financial Results and Highlights for First Quarter of 2009 3Health News:Isis Reports Strong Financial Results and Highlights for First Quarter of 2009 4Health News:Isis Reports Strong Financial Results and Highlights for First Quarter of 2009 5Health News:Isis Reports Strong Financial Results and Highlights for First Quarter of 2009 6Health News:Isis Reports Strong Financial Results and Highlights for First Quarter of 2009 7Health News:Isis Reports Strong Financial Results and Highlights for First Quarter of 2009 8Health News:Isis Reports Strong Financial Results and Highlights for First Quarter of 2009 9Health News:Isis Reports Strong Financial Results and Highlights for First Quarter of 2009 10
    ... The Self-Cath Closed System is ... a method for safe, simple catheterization ... urinary tract infections. It includes ... The new EasyOff tear tab ...
    ... Self-Cath family of 100% ... a variety of options ... Each catheter is made ... PVC and has smooth ...
    ... The Self-Cath family ... offers patients a variety ... self-catheterization. Each catheter ... medical grade PVC and ...
    ... family of 100% latex-free ... variety of options for ... catheter is made of ... and has smooth fire ...
    Medicine Products: